期刊文献+

超声评估乳癌患者腋下淋巴结转移的临床价值 被引量:7

The Value of Ultrasonography to Evaluate Axillary Lymph Node Metastasis in the Patients with Breast Carcinoma
下载PDF
导出
摘要 目的:通过对乳癌原发灶的灰阶超声,彩色多普勒(Color Doppler Flow Imaging,CDFI),频谱多普勒检查,评估腋下淋巴结有无转移。方法:术前运用超声检测122例乳癌患者原发灶的声学特性,术后根据腋下淋巴结有无转移分为两组,比较两组间年龄,原发灶的部位(象限分布),大小,内部回声,有无卫星灶,CDFI,频谱多普勒有无显著差异。结果:患者的年龄,内部回声,有无卫星灶,两组间无显著性差异;原发灶的大小,部位两组间有显著差异;CDFI显示:腋下淋巴结阳性组原发灶内血流比阴性组丰富(P<0.05);频谱多普勒显示:阳性组峰值流速(Vmax)高于阴性组(P<0.01),其中Vmax>33cm/s的14例患者腋下淋巴结均呈阳性。阻力指数(RI):两组间无显著差异,但如把RI=1的8位患者单独列组,两组间有显著差异(P<0.01)。结论:运用灰阶超声、多谱勒超声评价癌肿的声学特性,对判断腋下淋巴结状态,指导临床治疗,有一定帮助。 Objective: To scan breast cancer and evaluate axillary lymph node metastasis with gray- scale US,color Doppler and spectrum Doppler. Methods: One- hundred twenty two women with primary breast cancer were studied. For comparison of ultrasonography featrues (size, location, echo, satellite of cancer, CDFI, spectrum Doppler), patients were divided into two groups-, breast cancer with malignant LN and breast cancer with normal LN. Results: Age, echo and satellite of cancer had been demonstrated equally in breast cancer with malignant LN and breast cancer with normal LN. Size and location were demonstrated unequally in two groups. Color flow and Vmax were significantly higher in breast cancer with malignant LN. The Vmax were higher than 33cm/s in all 14 patients of breast cancer with malignant LN. RI were demonstrated equally in two groups. If 8 patients(RI = 1) separated and list another group, RI demonstrated unequally. Conclusion: Gray-scale US and color Doppler flow features may identify breast cancer with malignant LN and breast cancer with normal LN.
出处 《中国临床医学》 2002年第5期538-540,共3页 Chinese Journal of Clinical Medicine
关键词 腋下淋巴结转移 超声声像图 乳腺癌 淋巴结清扫术 Ultrasonography Breast neoplasm LN metastasis
  • 相关文献

参考文献2

二级参考文献31

  • 1[22]Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable bresat cancer[J]. Br J Cancer,1996,74:297
  • 2[23]Fisher B,Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors[J]. J Natl Cancer Inst, 1996,88:1529
  • 3[24]Klijn JGM, Blarney RW, Boccardo F, et al. Combination LHRH-agonist plus tamoxifen treatment is superior to medical castration alone in premenopausal metastatic breast cancer[J]. Breast Cancer Res Treat,1998,50:227(Abst)
  • 4[25]Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate[J]. J Clin Oncol,1998,16:453
  • 5[26]Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carinoma:results of a suvival update based on a combined analysis of data from two mature phase Ⅲ trials[J]. Cancer,1998,83:1142
  • 6[27]Bajetta E, Zilembo N, Barni S, et al. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse:endocrine and clinical results[J]. Ann Oncol,1997,8:649
  • 7[28]Kaufmann M, Bajetta E, Dirix LY. Survival advantage of exemestane over megestrol acetate in postmenopausal women with advanced breast cancer refractory to tamoxifen:results of a phase Ⅲ randomized double-blind study[J]. Proc Am Soc Clin Oncol,1999,18:42a
  • 8[29]Crown J, Raptis G, Hamilton N, et al. High-dose chemotherapy of breast cancer:current status and developmental strategies. Eur J Cancer,1995,31A:809
  • 9[30]O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol,1997,125:246
  • 10[31]Pegram M, Lipton A, Hayes DF, t al. Phase Ⅱ study of receptor-enhanced chemosensitivity using recombinant humanized anti-p158 HER2/neu monoclonal antibody plus cisplatin in patients with HER-2/new overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol,1998,16:2659

共引文献28

同被引文献13

  • 1杨明霞.超声检查对乳腺实性肿块内血液动力学研究[J].中国超声诊断杂志,2004,5(11):819-821. 被引量:10
  • 2刘月洁,张颖,付钰,凌广花,武敬平,王雪,李建国.彩色多普勒超声鉴别良恶性乳腺肿物的应用[J].中国超声医学杂志,2006,22(6):420-422. 被引量:57
  • 3潘丽玲,王良玉,周瑞莉.彩色多普勒超声对乳腺肿块的鉴别诊断分析[J].临床超声医学杂志,2006,8(8):478-480. 被引量:32
  • 4徐君镛 朱雪萍 等.彩色血流成像与频谱多普勒超声检查对乳腺良恶性肿块的鉴别诊断[J].超声临床杂志,1999,6(2):6-8.
  • 5Mder DD, Carson PL, Rubin JM, et al. Doppler ultrasoumd color flow imaging in the study of bresy cancer: Preliminary findings [J]. Ultrasound Med Biol, 1990,16 (6) :553.
  • 6[4]Alois H,Thomas R,Peter M,et al.New signs of breast cancer high resistance flowand variation in resistance indiceseval-uation by color Doppler sonography[J].Ultrasound Med Bi-ol,1997,23(6):851-856.
  • 7Adler D D,Carson P L,Rubin J M,et al.Doppler ultrasound color flow imaging in the study of breast cancer:Preliminary findings[J]. Ultrasound Med Biol.
  • 8徐君镛 朱雪萍 王纯杰 等.彩色血流成像与频谱多普勒超声检查对乳腺良恶性肿块的鉴别诊断.超声临床杂志,.
  • 9周永昌,郭万学.超声医学[M].第4版.北京:科学技术文献出版社,2002:885-886.
  • 10韩增辉,王全华,钱蕴秋,朱延光.能量多普勒显像鉴别乳腺肿块及其临床应用价值[J].中国超声医学杂志,1997,13(1):34-36. 被引量:55

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部